Venderink W, et al. - Purpose of this study was to compare clinically significant prostate cancer (csPCa) detection rates between magnetic resonance imaging (MRI)–transrectal ultrasound (TRUS) fusion-guided prostate biopsy (FGB) and direct in-bore MRI-guided biopsy (MRGB). No significant differences were found between FGB and MRGB in the detection of csPCa. The differences in detection ratios between both biopsy techniques are narrow with an increasing lesion size. This research warrants further studies to optimize selection of best biopsy modality.

Methods

• Researchers conducted a comparison of csPCa detection rates between FGB and MRGB.
• Enrolled patients had at least one prior negative TRUS biopsy; a Prostate Imaging Reporting and Data System (PI-RADS) 4 or 5 lesion and (3) a lesion size of ≥8 mm measured in at least one direction.
• They considered a Gleason score ≥7 being csPCa.
• They applied descriptive statistics with 95% confidence intervals (CI) to determine any differences.

Results

• They recruited 51 patients with FGB (59 PI-RADS 4 and 41% PI-RADS 5) and 227 patients with MRGB (34 PI-RADS 4 and 66% PI-RADS 5).
• Enrolled patients had a median age of 69 years (IQR, 65–72) and a median PSA level of 11.0 ng/ml (IQR, 7.4–15.1) and a median age of 67 years (IQR, 61–70), the median PSA 12.8 ng/ml (IQR, 9.1–19.0) within the FGB and the MRGB group, respectively.
• The obtained data indicates that detection rates of csPCA did not differ significantly between FGB and MRGB, 49 vs. 61%, respectively.